BAKER BROS. ADVISORS LP Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001263508
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q1 2024 · 87 positions · Total reported value $7.97B · Top-10 concentration 77.1% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 24.2% · 8 new · 6 cut · 8 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q1 2026 → Q2 2026): +14.7% · vs SPY -0.1% · Prev Value $16.51B — last quarter positions weighted by this quarter price moves · ranking
In its Q1 2024 13F filing, BAKER BROS. ADVISORS LP disclosed 87 equity positions with a combined reported value of $7.97B. The filing implies a focused portfolio: its ten largest positions account for 77.1% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.
The largest disclosed positions as of Q1 2024 were INCY ($2.06B), ONC ($1.65B), ACAD ($792.57M). By sector, the heaviest allocations are Health Care 95.9%, Materials 0.2%. Versus the prior quarter, allocation shifted toward Health Care (+2.2pp) and away from Other (-2.3pp).
Versus the prior quarter, BAKER BROS. ADVISORS LP opened 8 new positions, trimmed 6 and fully exited 8, a turnover rate of 24.2% of positions. The portfolio's overlap with the prior quarter was 80% of names.
The largest new positions opened in Q1 2024 were FATE ($13.35M), NMRA ($8.72M), DYN ($8.09M).
Of the 8 positions fully exited versus the prior quarter, the largest were MRTX ($242.13M), GRCL ($20.88M), DAWN ($14.60M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q1 2024)
- FATE Fate Therapeutics Inc · $13.35M
- NMRA NEUMORA THERAPEUTICS INC. · $8.72M
- DYN DYNE THERAPEUTICS INC · $8.09M
- SAGE SAGE THERAPEUTICS INC · $7.63M
- ALPN ALPINE IMMUNE SCIENCES INC · $3.23M
- FDMT 4D MOLECULAR THERAPEUTICS IN · $3.19M
- NAMS NEWAMSTERDAM PHARMA COMPANY · $2.29M
- VTVT VTV THERAPEUTICS INC · $2.29M
Fully Exited (vs previous quarter)
- MRTX MIRATI THERAPEUTICS INC · prev qtr: $242.13M
- GRCL GRACELL BIOTECHNOLOGIES INC · prev qtr: $20.88M
- DAWN DAY ONE BIOPHARMACEUTICALS I · prev qtr: $14.60M
- SPRY ARS PHARMACEUTICALS INC · prev qtr: $11.00M
- NVTAQ INVITAE CORP · prev qtr: $1.11M
- WHWK WHITEHAWK THERAPEUTICS INC · prev qtr: $508.49K
- BCEL ATRECA INC · prev qtr: $287.43K
Insider Transactions (Form 4)
Latest BAKER BROS. ADVISORS LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
| Transaction date | Activity | Security | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-11-06 | Buy | MADRIGAL PHARMACEUTICALS, INC. | 2,000 | $396.61 | SEC filing |
| 2026-11-06 | Buy | MADRIGAL PHARMACEUTICALS, INC. | 13,740 | $388.29 | SEC filing |
| 2026-11-06 | Buy | MADRIGAL PHARMACEUTICALS, INC. | 60,400 | $383.01 | SEC filing |
| 2026-11-05 | Buy | Kodiak Sciences Inc. | 81,729 | $98.51 | SEC filing |
| 2026-11-05 | Buy | Kodiak Sciences Inc. | 4,703 | $98.51 | SEC filing |
| 2026-11-04 | Buy | Kodiak Sciences Inc. | 151,916 | $98.51 | SEC filing |
| 2026-11-04 | Buy | Kodiak Sciences Inc. | 8,742 | $98.51 | SEC filing |
| 2026-11-04 | Buy | MADRIGAL PHARMACEUTICALS, INC. | 10,080 | $368.11 | SEC filing |
Fund Profile
Baker BROS. Advisors is an SEC-registered 13F filer based in New York, NY, United States. As of Q2 2026 it reported 83 US equity positions with a combined value of $19.13B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Firm Snapshot
- Headquarters: NEW YORK, NY, United States
- SEC registration: 801-73446 (status: Approved), registered 2012-03-05
- Regulatory AUM (Form ADV): $28.15B as of 2026-03-27
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 2 private funds, of which 2 hedge funds
Portfolio Structure
- 83 positions · $19.13B reported value (Q2 2026)
- Top 10 holdings = 74.7% of reported value
- Largest position: INCY (INCYTE CORP) at 18.2%
- Average position size: $230.45M
Sector Tilt
- Health Care 99.4%
- (classified holdings cover 99% of value)
Quarterly Activity
- Q2 2026: 8 new, 10 added, 6 reduced, 8 exited
- 59 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
AI Rebalance Analysis
Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
36.18M | $2.06B | 25.86% Form 4 · 1 → |
Hold | |
| 2 |
|
10.57M | $1.65B | 20.73% Form 4 · 1 → |
Hold | |
| 3 |
|
42.86M | $792.57M | 9.94% | Hold | |
| 4 |
|
1.97M | $526.01M | 6.60% Form 4 · 5 → |
Hold | |
| 5 |
|
6.40M | $277.24M | 3.48% | Hold | |
| 6 |
|
7.55M | $243.31M | 3.05% | Add | |
| 7 |
|
6.00M | $241.04M | 3.02% | Hold | |
| 8 |
|
27.53M | $124.69M | 1.56% | Add | |
| 9 |
|
4.94M | $123.08M | 1.54% | Add | |
| 10 |
|
5.84M | $106.52M | 1.34% | Add | |
| 11 |
|
1.52M | $98.50M | 1.24% | Reduce | |
| 12 |
|
17.31M | $91.05M | 1.14% Form 4 · 86 → |
Hold | |
| 13 |
|
7.41M | $78.14M | 0.98% | Reduce | |
| 14 |
|
9.55M | $77.99M | 0.98% | Hold | |
| 15 |
|
3.73M | $76.57M | 0.96% | Add | |
| 16 |
|
4.87M | $68.95M | 0.86% | Hold | |
| 17 |
|
2.71M | $68.54M | 0.86% | Add | |
| 18 |
|
1.47M | $68.47M | 0.86% | Hold | |
| 19 |
|
6.44M | $67.72M | 0.85% | Add | |
| 20 |
|
1.60M | $67.63M | 0.85% | Hold | |
| 21 |
|
151.22K | $59.54M | 0.75% | Hold | |
| 22 |
|
3.88M | $57.07M | 0.72% | Hold | |
| 23 |
|
2.81M | $55.43M | 0.69% | Hold | |
| 24 |
|
10.13M | $51.44M | 0.65% | Hold | |
| 25 |
|
1.68M | $49.69M | 0.62% | Hold | |
| 26 |
|
5.43M | $49.45M | 0.62% | Hold | |
| 27 |
|
10.12M | $47.99M | 0.60% | Hold | |
| 28 |
|
1.06M | $46.61M | 0.58% | Hold | |
| 29 |
|
3.37M | $45.47M | 0.57% | Add | |
| 30 |
|
993.68K | $42.78M | 0.54% | Hold | |
| 31 |
|
4.09M | $39.45M | 0.49% | Add | |
| 32 |
|
19.48M | $36.81M | 0.46% | Hold | |
| 33 |
|
4.92M | $34.66M | 0.43% | Hold | |
| 34 |
|
1.55M | $33.53M | 0.42% | Add | |
| 35 |
|
2.11M | $31.53M | 0.40% | Hold | |
| 36 |
|
169.93K | $30.24M | 0.38% | Hold | |
| 37 |
|
2.38M | $23.81M | 0.30% | Add | |
| 38 |
|
456.01K | $23.21M | 0.29% | Add | |
| 39 |
|
1.69M | $22.46M | 0.28% | Hold | |
| 40 |
|
2.78M | $22.11M | 0.28% | Hold | |
| 41 |
|
10.79M | $17.04M | 0.21% | Reduce | |
| 42 |
|
425.01K | $13.73M | 0.17% | Hold | |
| 43 |
|
2.50M | $13.36M | 0.17% | Hold | |
| 44 |
|
1.82M | $13.35M | 0.17% | New | |
| 45 |
|
545.43K | $12.07M | 0.15% | Add | |
| 46 |
|
4.00M | $11.49M | 0.14% | Hold | |
| 47 |
|
14.61M | $10.95M | 0.14% | Hold | |
| 48 |
|
247.64K | $10.39M | 0.13% | Hold | |
| 49 |
|
1.16M | $9.63M | 0.12% | Hold | |
| 50 |
|
343.00K | $9.31M | 0.12% | Hold | |
FAQ
What did BAKER BROS. ADVISORS LP buy in 2024-Q1?
In its 2024-Q1 13F filing, BAKER BROS. ADVISORS LP reported 87 equity positions worth $7.97B in aggregate; its largest disclosed positions were INCY ($2.06B), ONC ($1.65B), ACAD ($792.57M).
How large is BAKER BROS. ADVISORS LP's portfolio?
BAKER BROS. ADVISORS LP reported $7.97B of long equity holdings across 87 positions as of 2024-Q1. Top-10 holdings account for 77.1% of reported value.
What is BAKER BROS. ADVISORS LP's investment style?
HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.